Pluristem’s Placenta Derived Cells Chosen by European Commission’s Seventh Framework Program (FP7) Study for Treatment of Diastolic Heart Failure (DHF) in Type 2 Diabetic Patients Date: August 30, 2010 Client: Pluristem Therapeutics Inc. Summary: HAIFA, ISRAEL --(Business Wire)--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced that its PLX cell therapy product, derived from human placenta, a non-controversial, non-embryonic, adult stem cell source, was selected as the only cell therapy product candidate to enter into a study seeking treatments for diastolic heart failure (DHF) in the European Commission’s Seventh Framework Program (FP7). Pluristem is to receive a grant from the FP7 to cover study related R&D expenses.
		New Targets, Dual Agonists Increase Possibilities for Treating Diabetes Fritz French, Chief Executive Officer, Marcadia Biotech, Carmel, Ind. Date: August 26, 2010 Client: Marcadia Biotech, Inc. Summary: Diabetes is a common chronic disease affecting an estimated 285 million adults worldwide. This number will continue to grow as the population ages and becomes more obese—both risk factors for type 2 diabetes. The diabetes treatment market generated over $25 billion in 2009 and the number of patients is continuously rising.
		Roche Backs New Method for Drug Delivery to Cells Date: August 24, 2010 Client: Marcadia Biotech, Inc. Summary: The Swiss pharmaceutical giant Roche is throwing its weight behind an experimental technology that could be used to treat a number of diseases.
		Aragon: AR-gone Date: August Client: Aragon Pharmaceuticals Inc. Summary: Aragon Pharmaceuticals Inc. is developing small molecules that it hopes will be more potent than other secondgeneration hormone receptor antagonists in the clinic, and last week began a Phase I/II trial of its lead ARN-509 to treat castration-resistant prostate cancer. The company also is working on third-generation molecules that go one step further by programming the receptors for proteasomal degradation.
		EntreMed Reports Second Quarter 2010 Financial Results Date: August 16, 2010 Client: EntreMed, Inc. Summary: ROCKVILLE, MD – August 16, 2010 – EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six-month periods ending June 30, 2010.
		MedAssurant to Assist NCQA in the Development of Healthcare Quality Measures Date: August 12, 2010 Client: MedAssurant Inc. Summary: BOWIE, Md. – August 12, 2010 – MedAssurant Inc., a leading provider of data-driven healthcare solutions, today announced that it has entered into a definitive agreement with the National Committee for Quality Assurance (NCQA), the organization that maintains the Healthcare Effectiveness Data and Information Set (HEDIS ®)—the most widely used performance measurement tool in healthcare and a core component of the Medicare Star Rating system—to support the development of new measures of healthcare quality that NCQA is developing under a contract it has with the Centers for Medicare & Medicaid Services (CMS).
		Aragon Pharmaceuticals Doses First Patient in Phase 1/2 Clinical Trial of ARN-509 for Castration-Resistant Prostate Cancer Date: August 9, 2010 Client: Aragon Pharmaceuticals Summary: Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company’s lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).
		Pluristem’s PLX Cells Found to be Effective in Treating Neuropathic and Inflammatory Pain Date: August 9, 2010 Client: Pluristem Therapeutics Inc. Summary: HAIFA, Israel--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced the results of two separate pre-clinical studies in animal models which demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for both neuropathic and inflammatory nerve pain. These animal studies were conducted in collaboration with the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and the Department of Anesthesiology and Operative Intensive Care Medicine, both at the Charité-Universitätsmedizin of Berlin, Germany.
		Pluristem Appoints Diabetic Neuropathy and Vascular Disease Expert, Dr. Arisitdes Veves, to its Scientific Advisory Board Date: August 4, 2010 Client: Pluristem Therapeutics Inc. Summary: HAIFA, Israel--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it appointed Dr. Aristidis Veves to the company’s Scientific Advisory Board.
		Sterling Health Plans Expands Relationship With MedAssurant Date: August 4, 2010 Client: MedAssurant, Inc. Summary: BOWIE, Md. – August 4, 2010 – MedAssurant, Inc., a leading provider of data-driven healthcare solutions, today announced that Sterling Health Plans, a national provider of Medicare benefits, has expanded its relationship with MedAssurant through the selection of two key solutions to identify and close meaningful gaps in quality, utilization, documentation and risk score accuracy.
		Victory Pharma Completes Acquisition of Assets of MiddleBrook Pharmaceuticals Date: August 3, 2010 Client: Victory Pharma, Inc. Summary: SAN DIEGO, Aug. 3, 2010 – Victory Pharma, Inc. (“Victory”) today announced that it has completed the acquisition of substantially all of the assets of MiddleBrook Pharmaceuticals, Inc.(OTCQB: MBRKQ).
		MorphoSys Announces Clinical Milestone from Strategic Alliance Date: August 2, 2010 Client: MorphoSys AG Summary: MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it will receive a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial, using a HuCAL-derived, fully human antibody in the therapeutic area of musculoskeletal diseases. Today's news represents the second HuCAL-derived antibody to achieve this stage during the course of 2010, following a clinical milestone hit as part of the alliance with Centocor in June 2010.
		Aragon Pharmaceuticals Appoints Richard A. Heyman CEO Date: August 2, 2010 Client: Aragon Pharmaceuticals Summary: Aragon Pharmaceuticals today announced the appointment of company co-founder Richard A. Heyman, Ph.D., to the role of Chief Executive Officer. Additionally, esteemed scientists Ronald M. Evans, Ph.D., an expert in the area of hormone research and transcriptional regulation, and David J. Mangelsdorf, Ph.D., an authority on nuclear receptors and endocrine signaling, were added to the company's scientific advisory board.